

COVID-19 Therapeutics Update VDH Partners Call

December 17, 2021

Drugs for the outpatient treatment of mild to moderate Covid-19

- Monoclonal antibody therapy - 3 drugs, all have FDA Emergency Use Authorization
- REGEN-COV (Regeneron)
- Bam/Ete (Eli Lilly)
- Sotrovimab (GlaxoSmithKline)
- Monoclonal antibodies are likely underused and we are working with our communications partner to promote their use to physicians and patients

Drugs for the prevention of Covid-19

- Monoclonal antibody therapy - all meds have FDA Emergency Use Authorization
- One medication for pre-exposure prophylaxis = Evusheld (AstraZeneca)
- Drug given to people with weak immune system who are not expected to generate an adequate immune response to complete vaccination, OR can be used in people who are unable to be vaccinated because they had a severe reaction to the vaccine
- Two medications for postexposure prophylaxis (PEP) = REGEN-COV (Regeneron) and Bam/Ete (Eli Lilly)
- To prevent high-risk people exposed to Covid-19 from coming down with the illness

Oral antiviral drugs that are under review by the FDA

- Molnupiravir (Merck)
- Paxlovid (Pfizer)

- Each company has submitted an application packet to FDA for its drug to receive Emergency Use Authorization
- At this point, neither product has received an EUA and it's not clear when this might happen
- If these drugs receive an EUA, the initial quantities of the products are likely to be limited
- VDH will continue to monitor the situation with these products

Supply of and demand for Covid-19 therapeutics

- Every 2 weeks, Virginia receives an allocation of medication from the federal government (U.S. Dept of Health and Human Services)
- Recently, increase in demand for monoclonal antibody products
- VDH keeping a close watch on this situation and has already instituted measures to preserve existing supply of medication
- It is anticipated the supply of new medications will be limited when these products are initially released

Thank you and please contact me if questions:
Brooke.Rossheim@vdh.virginia.gov